How much does Mobocertinib cost in China?

Mobocertinib (Mobocertinib) is a drug used to treat non-small cell lung cancer (NSCLC) and belongs to a class of drugs called tyrosine kinase inhibitors. It is specifically designed to target mutations in the EGFR (epidermal growth factor receptor) gene, particularly in NSCLC patients with the T790M mutation.

Mobotinib is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same.

EGFR mutations are common in some NSCLC patients and are usually treated with EGFR inhibitors (such as gefitinib, icotinib, etc.). However, some patients develop resistance after treatment with these drugs, and one common resistance mechanism is the T790M mutation. Mobosetinib was developed to combat this resistance by effectively inhibiting the T790M mutation and thereby helping to control tumor growth.

Mobosetinib is an oral medication, and dosage and treatment plans usually need to be determined based on the patient's specific condition and the recommendations of the doctor. It has shown significant efficacy in some patients with EGFR-mutated NSCLC and is approved to treat these patients, particularly those who have tolerated other EGFR inhibitors. However, like all drugs, moboxetinib may cause adverse reactions, so patients need to be closely monitored and work with their doctor during treatment to ensure optimal treatment effectiveness and safety.